Kestra Advisory Services LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 656.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 94,335 shares of the medical instruments supplier’s stock after acquiring an additional 81,860 shares during the period. Kestra Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $16,886,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. TD Waterhouse Canada Inc. raised its holdings in Becton, Dickinson and Company by 17.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Northside Capital Management LLC lifted its position in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after acquiring an additional 9,494 shares in the last quarter. NewEdge Advisors LLC boosted its stake in Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Capital Analysts LLC boosted its stake in Becton, Dickinson and Company by 7.5% during the 2nd quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock valued at $12,651,000 after purchasing an additional 5,828 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth $3,353,000. Institutional investors own 86.97% of the company’s stock.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on BDX shares. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research note on Friday, August 7th. Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Bank of America lifted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Royal Bank Of Canada lifted their price objective on Becton, Dickinson and Company from $190.00 to $225.00 and gave the stock a “sector perform” rating in a report on Friday. Finally, Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $193.67.
View Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Up 0.2%
NYSE:BDX opened at $212.27 on Monday. The company has a market cap of $58.49 billion, a PE ratio of 51.27, a price-to-earnings-growth ratio of 14.26 and a beta of 0.22. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. The company has a 50 day simple moving average of $188.17 and a two-hundred day simple moving average of $170.28. Becton, Dickinson and Company has a 12 month low of $137.35 and a 12 month high of $214.88.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.11 billion. During the same period in the prior year, the firm earned $3.96 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Research analysts forecast that Becton, Dickinson and Company will post 13.27 earnings per share for the current year.
Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be issued a $1.06 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.
Becton, Dickinson and Company News Roundup
Here are the key news stories impacting Becton, Dickinson and Company this week:
- Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
- Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
- Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
- Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
- Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.
BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
